VSTM Q2 2024 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena

VSTMVerastem, Inc.

$388M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M

Gross Profit

$10M100.0% margin

Operating Income

-$18M-182.8% margin

Net Income

-$8M-82.6% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$106M

Total Liabilities

$66M

Stockholders' Equity

$40M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$0	—
Gross Profit	$10M	$0	—
Operating Income	-$18M	-$20M	+9.9%
Net Income	-$8M	-$24M	+66.0%